US Stock Insider Trading | Futai Pharmaceutical disclosed 10 insider transactions on February 23

K-LinePoet · 2026-02-24T01:27:20+00:00

February 23, 2026, Futai Pharmaceutical (VRTX) disclosed 10 insider transactions. Executive Sachdev Amit bought 25,000 shares on February 19, 2026.【Recent Insider Transactions】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD || --- | --- | --- | --- | --- | --- | --- | --- || February 23, 2026 | Executive | Sachdev Amit | February 19, 2026 | Sell | 1,848 | 465.80 | $860,800 || February 23, 2026 | Executive |

K-LinePoet

2026-02-24 01:27:20

On February 23, 2026, Fuh Tai Pharmaceuticals (VRTX) disclosed 10 insider trading transactions. Executive Sachdev Amit purchased 25,000 shares on February 19, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
2026-02-23	Executive	Sachdev Amit	2026-02-19	Sell	1,848	465.80	860,800
2026-02-23	Executive	Sachdev Amit	2026-02-19	Sell	7,241	469.61	3,400,400
2026-02-23	Executive	Sachdev Amit	2026-02-19	Sell	920	463.91	426,800
2026-02-23	Executive	Sachdev Amit	2026-02-19	Sell	2,730	465.05	1,269,600
2026-02-23	Executive	Sachdev Amit	2026-02-19	Sell	10,300	467.75	4,800,500
2026-02-23	Executive	Sachdev Amit	2026-02-19	Sell	19,700	468.57	9,213,000
2026-02-23	Executive	Sachdev Amit	2026-02-19	Buy	23,500	155.57	3,652,600
2026-02-23	Executive	Sachdev Amit	2026-02-19	Buy	25,000	187.53	4,693,100
2026-02-23	Executive	Sachdev Amit	2026-02-19	Sell	4,237	471.43	1,997,400
2026-02-23	Executive	Sachdev Amit	2026-02-19	Sell	11,700	470.54	5,511,000

[Company Information]

Vertex Pharmaceuticals Incorporated was founded in 1989 in Massachusetts. It is a global biotechnology company dedicated to scientific innovation, aiming to create transformative medicines for individuals with serious diseases, especially in specialized markets. The company has developed approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta-thalassemia, and acute pain. It continues to innovate and advance next-generation clinical and research projects across various serious diseases, including IgA nephropathy and type 1 diabetes.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.